Sera Prognostics, Inc. (SERA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Ms. Zhenya Lindgardt M.B.A.
|
President, CEO & Director | 1.01M | -- | 1974 |
|
Dr. John J. Boniface Ph.D.
|
Chief Scientific Officer | 619.78k | -- | 1962 |
|
Dr. Gregory C. Critchfield M.D., M.S.
|
Executive Director | 35k | -- | 1953 |
|
Dr. Paul Kearney Ph.D.
|
Chief Data Officer | 600.28k | -- | 1968 |
|
Mr. Scott Gleason
|
CFO & Treasurer | -- | -- | 1979 |
|
Mr. Robert G. Harrison
|
Chief Information Officer | 384.18k | -- | 1966 |
|
Ms. Jennifer Zibuda
|
Head of Investor Relations | -- | -- | -- |
|
Mr. Benjamin G. Jackson J.D.
|
General Counsel & Corporate Secretary | 410.75k | -- | 1979 |
|
Mr. Austin Aerts
|
Advisor | 367.62k | -- | 1987 |
|
Mr. Lee Anderson
|
Chief Commercial Officer | -- | -- | -- |
Sera Prognostics, Inc.
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 71
Description
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Corporate Governance
Upcoming Events
November 4, 2026 at 9:00 PM UTC
Sera Prognostics, Inc. Earnings Date
